MICROBE will provide the EU a frontrunner position for a future first-in-human clinical trial using BEV nanotherapeutics in anti-cancer treatment.

Project description

Emerging evidence from cancer patients and mouse models indicates that gut bacteria affect response to immune checkpoint inhibitors (ICI). As a result, modification of gut bacteria by dietary changes, probiotics and fecal transplantations are explored but a huge gap remains to gain clinical application.
Limiting factors are the lack of mechanistic knowledge on how gut bacteria impact ICI response, the need of antibiotics to treat infections in cancer patients and gut resilience to exogenous bacterial colonization.

Bacteria release nanometer-sized extracellular vesicles (BEV), loaded with specific pathogen-associated molecular patterns (PAMP), which possess multiple favorable characteristics for clinical application but remain minimally explored in oncology. Recently, MICROBE’s research group pioneered the discovery of gut-derived immunomodulatory BEV in the systemic circulation (sysBEV) of non-septicemic cancer patients. The research group hypothesizes that sysBEV direct ICI response by initiating cytokine release to instruct innate and adaptive anti-tumor immunity. The overall scientific objective of the ERC-CoG project is to establish an innovative nanotherapeutic strategy using non-replicating BEV nanoparticles as a game changer to establish a safe but potent and durable ICI response. Hereto, MICROBE will analyse cancer patient biospecimens to address a number of fundamental questions with regard to BEV characteristics that are essential to ICI response and implement this know-how to formulate BEV nanotherapeutics from gut bacteria of healthy donors and ICI responsive cancer patients. The optimal administration route, treatment dosage, pharmaco-kinetics and -dynamics will be established and the synergism between BEV nanotherapeutics and ICI will be elucidated using clinically relevant mouse models. In conclusion, MICROBE will provide the EU a frontrunner position for a future first-in-human clinical trial using BEV nanotherapeutics in anti-cancer treatment.